M2 PRESSWIRE-August 26, 2019-: Retinal Vein
Occlusion (RVO) Market 2019 Global Analysis, Size, Share, Growth, Leading Players, Merger, Acquisition, Opportunity, Competitive Landscape with Regional Outlook To 2023
Graybug Vision, a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (AMD), diabetic macular oedema (DME), retinal vein
occlusion (RVO), and primary open angle glaucoma, has secured an USD80m Series C financing, it was reported yesterday.
The US Food and Drug Administration (FDA) has approved the Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA (aflibercept) Injection prefilled syringe to treat neovascular (wet) age-related macular degeneration (Wet AMD), macular edema following retinal vein
occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR).
Eylea, a vascular endothelial growth factor, is already approved four retinal conditions: neovascular wet age-related macular degeneration, macular edema following retinal vein
occlusion, diabetic macular edema and diabetic retinopathy.
Kodiak Sciences announced positive interim results from the ongoing Phase 1b study of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate in patients with anti-VEGF treatment-naive neovascular age-related macular degeneration, diabetic macular edema, and macular edema due to retinal vein
Keywords: Avastin, Bevacizumab, Branch retinal vein
occlusion, Intravitreal injections, Vascular endothelial growth factor.
occlusion (RVO) is a common retinal vascular disease, and often contributes to the occurrence of visual decline or loss, especially for middle-aged or elderly individuals (1).
The retina is full of fluid bubbles (dark areas), resulting from a blockage in one of the branches of a main retinal vein
A medial officer explained in the report that the disease could be caused by several medical conditions such as hypertension, retinal vein
occlusion (a blockage of a retinal vein
Unlike classic central retinal vein
occlusion, patients suffering from this disease are usually healthy and younger than 50 years of age.
The software should not be used to screen for diabetic retinopathy in patients who've had laser treatment, surgery, or injection in the eye or have any of the following conditions: persistent vision loss, blurred vision, floaters, previously diagnosed macular edema, severe non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy, or retinal vein
occlusion, according to the FDA.